Industry
Companies, platforms, regulation and the business of retinal technology.
Understand the field.
FDA-Cleared AI for Diabetic Retinopathy: How the U.S. Market Evolved
Retinal AI has moved from a regulatory first into a defined device category. The harder questions now are deployment, evidence and what clearance actually means.
Home OCT and Remote Retina Monitoring: From Device to Care Model
Moving OCT beyond the clinic could change how retinal disease is monitored—but the real innovation is the care pathway built around the scan.
The Retina Imaging Stack: Why Workflow Is Becoming Part of the Product
OCT, widefield imaging, AI and data review are converging into connected platforms. That changes how retinal technology companies compete.
What a Phase 3 Retina Gene Therapy Program Actually Has to Prove
A late-stage trial is a major milestone, but reaching Phase 3 is not the same as proving a retinal gene therapy works, lasts or can be delivered at scale.
Aflibercept Biosimilars, Longer-Acting Drugs and the Economics of Retina Care
Retina therapeutics are entering a more competitive era where efficacy, durability, price, interchangeability and treatment burden all shape value.
Retina Industry Watch 2026: The Milestones Worth Following
A living tracker for meaningful regulatory decisions, late-stage trials, imaging platforms and care-model shifts across the retina ecosystem.